BiotechTube

Famitinib + Cisplatin

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Locally Advanced Nasopharyngeal Carcinoma

Conditions

Locally Advanced Nasopharyngeal Carcinoma

Trial Timeline

Oct 1, 2011 → Jan 1, 2016

NCT ID
NCT01462474

About Famitinib + Cisplatin

Famitinib + Cisplatin is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Locally Advanced Nasopharyngeal Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01462474. Target conditions include Locally Advanced Nasopharyngeal Carcinoma.

What happened to similar drugs?

5 of 20 similar drugs in Locally Advanced Nasopharyngeal Carcinoma were approved

Approved (5) Terminated (1) Active (14)
✅letrozoleJiangsu Hengrui MedicineApproved
✅FulvestrantAstraZenecaApproved
✅PazopanibNovartisApproved
✅LetrozoleNovartisApproved
✅Trastuzumab emtansineRocheApproved
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01462474Phase 1Completed

Competing Products

20 competing products in Locally Advanced Nasopharyngeal Carcinoma

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
Tadalafil + GemcitabineEli LillyPhase 1
29
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
44
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
36
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
39
zolbetuximabAstellas PharmaPre-clinical
30
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
39
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
enfortumab vedotin (EV)Astellas PharmaPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
ASP3082Astellas PharmaPhase 2
42
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )Sun PharmaceuticalPhase 2
31